AbCellera Biologics (ABCL) Revenue (2020 - 2026)

AbCellera Biologics has reported Revenue for 7 years, with the latest figure at $8.3 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 96.34% year-over-year to $8.3 million; the trailing twelve-month figure through Mar 2026 stood at $79.2 million (up 242.66% YoY), and the FY2025 full-year result was $75.1 million, up 160.56% from the prior year.
• Revenue for Q1 2026 stood at $8.3 million, down from $44.9 million in the prior quarter.
• The five-year high for Revenue was $316.6 million in Q1 2022, with the low at $4.2 million in Q1 2025.
• Historically, Revenue has averaged $37.4 million across 5 years, with a median of $10.0 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue surged 1740.65% — and 2023, when it plunged 96.15%.
• AbCellera Biologics' Revenue stood at $21.5 million in 2022, then tumbled by 57.4% to $9.2 million in 2023, then sank by 44.98% to $5.0 million in 2024, then jumped by 788.18% to $44.9 million in 2025, then plunged by 81.46% to $8.3 million in 2026.
• The last three Revenue figures came in at $8.3 million (Q1 2026), $44.9 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.